Skip to main content
SpringerLink
Log in

Topical and Intraurethral Therapy

  • Chapter
Male Sexual Function

Part of the book series: Current Clinical Urology ((CCU))

  • 143 Accesses

Abstract

Until the mid 1990s (1), the only practical method of delivering vasoactive substances to the penile erectile tissues was by direct injection into the copora cavernosa. The short-term efficacy of intracavernosal injection (ICI) therapy has ranged anywhere from 40 to 80%, and this form of therapy clearly revolutionized the nonsurgical approach to treatment of erectile dysfunction (ED). ICI has also enjoyed widespread acceptance by patients and urologists. However, despite its initial acceptance, 31–80% of men using such therapies eventually discontinue treatment for reasons relating to pain, loss of effectiveness, aversion to self-injection, and lack of interest, with dropout rates approaching 50% at one year (1–3). This de facto dissatisfaction with proven effective treatments is the rationale for alternative routes for the delivery of vasoactive substances.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lakin MM, Montague DK, Medendorp SV, Tesar L, Schover LR. Intracavernous injection therapy: analysis of results and complications. J Urol 1980; 143: 1138.

    Google Scholar 

  2. Irwin MB, Kata EJ. High attrition rate with intracavernous injection of prostaglandin El for impotency. Urology 1994; 48: 84.

    Article  Google Scholar 

  3. Valdevenito R, Melman A. Intracavernous self-injection pharmacotherapy program: analysis of results and complications. Int J Impotence Res 1994; 6: 81.

    CAS  Google Scholar 

  4. Dretler SP, Klein LA. The eradication of intraurethral condyloma accuminata with 5 percent 5-fluorouracil cream. J Urol 1975; 113: 195.

    PubMed  CAS  Google Scholar 

  5. Weimar GW, Milleman LA, Reiland TL, Culp DA. 5-fluorouracil urethral suppositories for the eradication of condyloma accuminata. J Urol 1978; 120: 174.

    PubMed  CAS  Google Scholar 

  6. Panacek E, Benenger P, Albertson T. Lidocaine toxicity from intraurethral administration. Ann Emerg Med 1984; 13: 483.

    Article  PubMed  CAS  Google Scholar 

  7. Yatscoff RW, Honcharik N, Tenenbein M. Systemic absorption of intraurethral lidocaine. CMAJ 1987; 137: 992.

    PubMed  CAS  Google Scholar 

  8. Sundaram MB. Seizures after intraurethral instillation of lidocaine. CMAJ 1987; 137: 219.

    PubMed  CAS  Google Scholar 

  9. Mahler JC, Perry S, Sutton B. Intraurethral cocaine administration. JAMA 1988; 259: 3126.

    Article  PubMed  CAS  Google Scholar 

  10. Jackson SC, Walker JS. Self-administered intraurethral chlorpromazine: an unusual cause of priapism. Am J Emerg Med 1991; 9: 171.

    Article  PubMed  CAS  Google Scholar 

  11. Padma-Nathan H, Keller T, Poppiti R, et al. Hemodynamic effects of intraurethral alprostadil: the medicated urethral system for erection (MUSE). J Urol 1994; 151: 469.

    Google Scholar 

  12. Tam PY, Keller T, Poppiti R, Gesundheit N, Padma-Nathan H. Hemodynamic effects of transurethral alprostadil measured by color duplex ultrasonography in men with erectile dysfunction. J Urol 1998; 160: 1321.

    Article  PubMed  CAS  Google Scholar 

  13. Wolfson B, Pickett S, Scott NE, DeKernion JB, Rajfer J. Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology 1993; 42: 73.

    Article  PubMed  CAS  Google Scholar 

  14. Palmer LS, Valcic M, Melman A, Giraldi A, Wagner G, Christ GJ. Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol 1994; 152: 1308.

    PubMed  CAS  Google Scholar 

  15. Lee SW, Wang HZ, Zhao W, Ney P, Brink PR, Christ GJ. Prostaglandin El activates the large-conductance Kca channel in human corporal smooth muscle cells. Int J Impot Res 1999; 11: 189.

    Article  PubMed  CAS  Google Scholar 

  16. Padma-Nathan H, Bennett A, Gesundheit N, Hellstrom W, Henry D, et al. Treatment of erectile dysfunction by the medicated urethral system for erection (MUSE). J Urol 1995; 153 (supplement): 472A.

    Article  Google Scholar 

  17. Padma-Nathan H, Hellstrom W, Kaiser F, Labasky R, Lue T, Nolten W, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336: 1.

    Article  PubMed  CAS  Google Scholar 

  18. Williams G, Abbou CC, Amar ET, Desvaux P, Ram TA, Lycklama A, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Brit J Urol 1998; 81: 889.

    Article  PubMed  Google Scholar 

  19. Fulgham PF, Cochran JS, Denman IL, Feagins BA, Gross MB, Kadesky KT. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998; 160: 2041.

    Google Scholar 

  20. Engel JD, McVary KT. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy Urology 1998; 51: 687.

    PubMed  CAS  Google Scholar 

  21. Costabile RA, Spevak M, Fishman IJ, Govier FE, Hellstrom W, Shabsigh R. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998; 160: 1325.

    Article  PubMed  CAS  Google Scholar 

  22. Benevides MD, Carson CC. Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis. J Urol 2000; 163: 785.

    Article  PubMed  CAS  Google Scholar 

  23. Bodner DR, Haas CA, Krueger B, Seftel AD. Intraurethral alprostadil for treatment of erectile dysfunction in patients with spinal cord injury. Urology 1999; 53: 199.

    Article  PubMed  CAS  Google Scholar 

  24. Peterson CA, Bennett AH, Hellstrom W, Kaiser FE, Morely JE, Nemo KJ, et al. Erectile response to transurethral alprostadil, prazosin and alprostadil-prazosin combinations. J Urol 1998; 159: 1523.

    Article  PubMed  CAS  Google Scholar 

  25. Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with suboptimal response to either alprostadil or sildenafil monotherapy. Eur Urol 2000; 38: 30.

    Article  PubMed  CAS  Google Scholar 

  26. Becher E, Borghi M, Momesso A, et al. Penile hemodynamic findings with a new topical formulation of alprostadil. J Urol 1998; 159 (5 Suppl): 239.

    Google Scholar 

  27. McVary KT, Polepalle S, Riggi S, Pelham RW. Topical PGE-1/SEPA gel for the treatment of erectile dysfunction. J Urol 1999; 162: 726.

    Article  PubMed  CAS  Google Scholar 

  28. Gurny R, Teubner A. Dermal and Transdermal Drug Delivery: New Insights and Perspectives. Wiss. Verl.-Ges. Stuttgart: 1993.

    Google Scholar 

  29. Maibach HI, Feldman RJ, Milby TH, Serat WF. Regional variation in percutaneous penetration in man. Arch Environ Health 1971; 23: 208.

    Article  PubMed  CAS  Google Scholar 

  30. Kim ED, el-Rashidy R, McVary KT. Papaverine topical gel for treatment of erectile dysfunction. J Urol 1995; 153: 361–365.

    Article  PubMed  CAS  Google Scholar 

  31. Clark RV, Murray FT, Hirshkowitz M, Ferry J, Lin T, Murphy TC, et al. Treatment of erectile dysfunction in men with diabetes mellitus using a penetration-enhanced topical minoxidil solution. J Andrology, January/February supplement: abstract 1994; 140: p. 55.

    Google Scholar 

  32. Borges FD. A new approach to the pharmacologic treatment of impotence. Int J Impot Res 1994; 6: 137.

    PubMed  CAS  Google Scholar 

  33. Kim ED, McVary KT. Topical Prostaglandin-El for the treatment of erectile dysfunction. J Urol 1995; 153: 1828.

    Article  PubMed  CAS  Google Scholar 

  34. Samour CM, Donaruma LG, Daskalakis S, Fulton BS, Marty JP, Dervault AM, et al. A new class of percutaneous absorption enhancers. Proc Intern Symp Control Rel Bioact Mater 1989; 16: 183.

    Google Scholar 

  35. Pelham R, Samour C. SEPA-009-safety and efficacy studies of a broad spectrum transdermal enhancer. Proc Intern Symp Control Rel Bioact Mater 1995; 22: 694.

    Google Scholar 

  36. Morganti F, Bramanti E, Solaro R, Nannipieni E, Narducci P, Krauser SF, et al. Thermal and spectroscopic characterization of interactions between 2-Nonyl-1,3-dioxolane and stratum corneum components. J Control Rel (in press).

    Google Scholar 

  37. Mudd JW. Impotence responsive to glyceryl trinitrate. Amer J Psych 1977; 134: 922.

    CAS  Google Scholar 

  38. Owen JA, Saunders F, Harris C, Fenemore J, Reid K, Surridge D, et al. Topical nitroglycerin: a potential treatment for impotence. J Urol 1989; 141: 546.

    PubMed  CAS  Google Scholar 

  39. Nunez BD, Anderson DC Jr. Nitroglycerin ointment in the treatment of impotence. J Urol 1993; 150: 1241–1243.

    PubMed  CAS  Google Scholar 

  40. Cavallini G. Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence. J Urol 1991; 146: 50.

    PubMed  CAS  Google Scholar 

  41. McVary KT, Kim ED. Topical PGE1 gel as treatment for erectile dysfunction. J Urol 1995; 153 (suppl): 982A.

    Google Scholar 

  42. Becher E, Momesso A, Borghi M, et al. Topical prostaglandin El (PGE1) for erectile dysfunction. (abstract) J Urol 1996; 155 Suppl: 296A.

    Google Scholar 

  43. Donatucci CF, Lue TF. The combined intracavernous injection and stimulation test: diagnostic accuracy. J Urol 1992; 148: 61.

    PubMed  CAS  Google Scholar 

  44. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397.

    Article  PubMed  CAS  Google Scholar 

  45. Moltz H. E-series prostaglandins and arginine vasopressin in the modulation of male sexual behavior. Neurosci Biobehav Rev 1990; 14: 109.

    Article  PubMed  CAS  Google Scholar 

  46. Vasko MR. Prostaglandin-induced neuropeptide release from spinal cord. Progress Brain Res 1995; 104: 367.

    Article  CAS  Google Scholar 

  47. McCall JM, Aiken JW, Chidester CG, Du Charme DW, Wendling MG. Pyrimidine and triazine 3-oxide sulfates: a new family of vasodilators. J Med Chem 1983; 26: 1791.

    Article  PubMed  CAS  Google Scholar 

  48. Virag R. Intracavernous injection of papaverine for erectile failure. Letter to the Editor, Lancelet 1982; 2: 938.

    Article  CAS  Google Scholar 

  49. Tanaka T. Papaverine hydrochoride in periphiral blood and the degree of penile erection. J Urol 1990; 143: 1135.

    PubMed  CAS  Google Scholar 

  50. Shaaya AN, Kraus C, Bauman DH, Ritschel WA. Pharmacokinetics and bioavailability of papavervine HC1 after intravenous, intracorporeal and penis topical application in beagle dogs. Methods Findings Exp Clin Pharm 1992; 14: 373.

    CAS  Google Scholar 

  51. Chiang HS, Kao YH, Sheu MT. Papaverine and prostaglandin El gel applications for impotence. Ann Acad Med Singapore 1995; 24: 767.

    PubMed  CAS  Google Scholar 

  52. Levine SB, Althof SE, Turner LA, Risen CB, Bodner DR, Kursh ED, et al. Side effects of self administration of intracavernous papaverine and phentolamine for the treatment of impotence. J Urol 1989; 141: 54.

    PubMed  CAS  Google Scholar 

  53. Virag R, Shoukry K, Floresco J, Nollet F, Greco E. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8 year experience with 615 cases. J Urol 1991; 145: 287.

    PubMed  CAS  Google Scholar 

  54. Govier FE, McClure RD, Wei1ssman RM, Gibbons RP, Pritchett TR, Kramer-Levien D. Experience with triple drug therapy in a pharmacological erection program. J Urol 1993; 150: 1822.

    PubMed  CAS  Google Scholar 

  55. Heaton JP, Morales A, Owen J, Saunders FW, Fenemore J. Topical glycerylnitrate causes measurable penile arterial dilation in impotent men. J Urol 1990; 143: 729.

    PubMed  CAS  Google Scholar 

  56. Sonksen J, Biering-Sorensen F. Transcutaneous nitroglycerin in the treatment of erectile dysfunction in spinal cord injured. Paraplegia 1992; 30: 554.

    Article  PubMed  CAS  Google Scholar 

  57. Meyhoff HH, Rosenkilde P, Bodker A. Non-invasive management of impotence with transcutaneous nitroglycerin. Br J Urol 1992; 69: 88.

    Article  PubMed  CAS  Google Scholar 

  58. Padma-Nathan H, Tam PY, Place VA, Aboseif SRG, Lue TF. Improved erectile response to transurethral alprostadil by the use of a novel, adjustable penile band. J Urol 1997; 157 (suppl): 704A.

    Article  Google Scholar 

  59. Lewis RW. Combined use of transurethral alprostadil and an adjustable penile constriction band in men with erectile dysfunction: results from a multicenter trial. J Urol 1998; 159 (suppl): 906A.

    Google Scholar 

  60. Becher EF, Bechara A, Casabe A. Topical alprostadil produces significant clitoral hemodynamic changes. J Urol 2000; 163 (suppl): 652A.

    Article  Google Scholar 

  61. Werthman P, Rafjer J. MUSE therapy: preliminary clinical observations. Urology 1997; 50: 809–811.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John C. Hairston MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edgardo F. Becher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin T. McVary MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Indiana University Medical Center, Indianapolis, Indiana, USA

    John J. Mulcahy MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hairston, J.C., Becher, E.F., McVary, K.T. (2001). Topical and Intraurethral Therapy. In: Mulcahy, J.J. (eds) Male Sexual Function. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-098-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-098-8_12

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5701-9

  • Online ISBN: 978-1-59259-098-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation